Sugammadex

Details:

Hangzhou Benoy Chemical Co., Ltd is a scientific and technological enterprise dedicated to the R & D, production and operation of chemical raw materials, pharmaceutical intermediates and APIs. At present, the company has one R & D center and two production bases. The company has more than 10 full-time personnel engaged in the research and development of APIs and pharmaceutical intermediates, including 2 with doctor's degree, 5 with master's degree, 2 with Professor of Zhejiang University of technology as the chief consultant of the company, with strong scientific research force and rich practical experience. The laboratory is equipped with advanced ultra-high performance liquid chromatography, gas chromatography and relatively complete conventional experimental equipment. Many products have been successfully developed and put into industrial production. The company adheres to the quality and environment policy of "customer first, continuous innovation", and excellent products win good market reputation for the company. At present, the products are exported to Europe, the United States, Southeast Asia and other countries and regions. It is the company's business philosophy to guide technology with information, guarantee quality with technology and win market with quality. The company will give full play to its own advantages and devote itself to the specialization and serialization of pharmaceutical intermediates, so as to provide customers with high-quality, environmental protection and safety products. The company will also be honest, trustworthy, mutually beneficial and co-existence purposes, is willing to sincerely cooperate with customers at home and abroad, hand in hand.

Sugammadex is a selective relaxant binding agent indicated for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide during surgery in adults. Rocuronium bromide and vecuronium bromide are neuromuscular blocking medications that cause temporary paralysis and are especially useful for general anesthesia, ventilation, or tracheal intubation that patients may require for surgery. Sugammadex provides a new treatment option to reverse the effects of those medications and possibly help patients recover sooner post-surgery. Sugammadex (brand name Bridion) is marketed by Merck Sharp and Dohme, and was approved by the United States FDA on December 15, 2015.